PTCT PTC Therapeutics, Inc.

PTC (PTC) and Fair Isaac are both owned for software that customers find hard to replace. PTC sells more to manufacturers it already serves, while Fair Isaac has raised the price of its mortgage credit score. Fair Isaac stock has lost 46% in a month, while PTC stock has lost 12.5%. Which of the two is gaining the firmer grip on its customers.

PTC Therapeutics (PTCT) heads into its next earnings report with consensus EPS forecasts unchanged over the past month, even as the stock ticked 0.6% higher in the last session to close at $68. Recent trading has been choppy for PTC Therapeutics, with the share price down 3.9% over the last session to $65.37 and weaker momentum over the past quarter. However, the 3-year total shareholder return of 173.3% and 5-year total shareholder return of 66.4% still reflect a materially stronger long-run...

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Both software players are riding the AI wave, but PTC offers a clearer forward path with stronger growth and profitability, while Oracle asks investors to fund a massive, costly buildout.

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

The bank is looking well beyond mega-cap technology.

PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.

Recent analysis of PTC Therapeutics points to price targets clustering in a broad band that runs from the mid US$80s up to US$130. Analysts link these higher targets to supportive views on Sephience performance, expectations for the broader pipeline, and debate over how much of that potential is already reflected in the current share price. As you read on, you will see how these shifting targets fit into the wider narrative and how to track the story as it develops. Analyst Price Targets...

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PTC Therapeutics (NASDAQ:PTCT) reported second-quarter total revenue of $361 million and raised its 2026 outlook, citing continued growth from its Sephience launch and greater durability than expected in its Duchenne muscular dystrophy franchise. Chief Executive Officer Dr. Matthew Klein said the c

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PTC Therapeutics Inc (PTCT) reports record Q2 2026 revenue of $361 million, driven by strong Sephience uptake, leading to raised full-year guidance and a robust pipeline outlook.

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.

QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.

This insider maintains 63,198 shares across direct and indirect accounts while holding 45,036 derivative securities.